DXCM vs RMD
Dexcom Inc (DXCM) and Resmed Inc (RMD) are both filed with the SEC under Surgical & Medical Instruments & Apparatus. The two are within rounding of one another by market cap ($33.7B and $34.0B); DXCM trades at the higher fiscal-year P/E (42.7× against 24.8×); RMD reports the higher net margin (27.2% against 17.9%); DXCM grew sales faster over three years (+17.0% against +11.9%); and over the past year DXCM returned +21.0% against RMD's -12.1%.
| DXCM | RMD | |
|---|---|---|
| Last close | $90.82 | $240.33 |
| Market cap | $33.7B | $34.0B |
| P/E (FY) | 42.7× | 24.8× |
| P/S | 7.2× | 6.6× |
| EV/EBITDA | — | 17.6× |
| Gross margin | 60.1% | 59.4% |
| Operating margin | 19.6% | 32.7% |
| Net margin | 17.9% | 27.2% |
| Return on equity | 34.5% | 25.9% |
| Sales growth (3y) | +17.0% | +11.9% |
| EPS growth (3y) | +36.6% | +21.5% |
| Dividend yield | — | 0.9% |
| 1-year return | +21.0% | -12.1% |
Screener snapshot — prices as of 2026-08-28. Each side's last close is the most recent session the snapshot holds for that company, which can be an earlier one, and its 1-year return is measured to that close. Market caps struck on 2026-08-27. Last close, market cap and the 1-year return are price figures; every other row is computed over the company's latest filed fiscal year, and the two differ: DXCM FY2025 (ended 2025-12-31); RMD FY2025 (ended 2025-06-30). — not published for this company. A ratio goes unpublished for more than one reason: a component the calculation needs is not on file, the filing does not tag the line it is read from, or the calculation is not defined on the filed basis — EV/EBITDA is not printed on non-positive EBITDA, and return on equity is not computed on a zero or negative equity base.
Who holds them, and who has traded them
| DXCM | RMD | |
|---|---|---|
| Institutional holders (13F) | 953 | 933 |
| Insider buyers − sellers (180d) | -5 | -3 |
| Congressional trades disclosed (180d) | 2 | 1 |
| Executive-branch officials on file — trades disclosed (180d) | 9 | 9 |
Counts only. The congressional figures count transactions dated in the trailing 180 days and disclosed in STOCK Act periodic transaction reports; amounts are filed as ranges and are never summed. The executive-branch figures count the same window of transactions, and they are scoped to one roster. The officials OGE posts for direct download. Insider buyers − sellers counts distinct people filing open-market Form 4 purchases minus distinct people filing open-market sales over the trailing 180 days, capped at ±5.
DXCM vs RMD: common questions
- Is DXCM bigger than RMD?
- RMD carries the larger market cap — $34.0B against $33.7B, both struck on 2026-08-27.
- Which trades at a higher P/E, DXCM or RMD?
- DXCM, at a fiscal-year 42.7× against 24.8× for RMD. Both are price ÷ latest full-year diluted earnings per share, not a trailing-twelve-month P/E.
- How have DXCM and RMD performed over the past year?
- DXCM returned +21.0% and RMD -12.1%, measured on the trailing calendar year to the last close.
- How many institutions hold DXCM and RMD?
- 953 13F filers report a position in DXCM and 933 in RMD, on the latest quarter in the panel.
- Are DXCM and RMD in the same industry?
- Both are filed with the SEC under Surgical & Medical Instruments & Apparatus, which is the classification this pairing is built on.
DXCM overview → · RMD overview → · DXCM institutional ownership → · RMD institutional ownership → · Congress and DXCM → · Congress and RMD → · Executive branch and DXCM → · Executive branch and RMD →
More in Surgical & Medical Instruments & Apparatus: BDX vs BSX · BDX vs DXCM · BDX vs MMM · BDX vs RMD
Stock comparisons lists every pair this site publishes.
Source: SPZCO — https://spzco.com/vs/dxcm-vs-rmd